Abstracts Archive - Page 167 of 2607 - ACR Meeting Abstracts

Abstract Number: 0896 • ACR Convergence 2025
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
marc Corbera-bellalta¹, Nuria Farran-Centelles², Nina Visocnik¹, Sergio Prieto-Gonzalez³, Jose hernandez-rodriguez⁴, javier Marco-hernandez⁵, Georgina Espigol-Frigolé¹ and Maria Cid⁶, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Autoimmune diseases, Barcelona, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic. University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁵Hospital Clinic.University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁶Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Patients with giant-cell arteritis (GCA) are in an unmet need for reduction of GC exposure because of the high incidence of GC-related side effects…
Abstract Number: 0968 • ACR Convergence 2025
Mesenchymal Stromal Cells in Systemic Sclerosis are Dysfunctional and Have a Profibrotic and Senescent Phenotype
Marianela Brizio¹, Benoit Brilland¹, Maximilien Lora², Mathieu Mancini¹, David Langlais¹, Marie Hudson³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Mesenchymal stromal cells (MSCs) are non-hematopoietic multipotent cells with immunomodulatory, proangiogenic, and antifibrotic properties. MSC functions are mediated by paracrine soluble factors and small…
Abstract Number: 0938 • ACR Convergence 2025
Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
Melodie Zaknoun¹, Doaa Tehawey¹, Baruh Polis¹ and Chaim Putterman², ¹Azrieli Faculty of Medicine, Safed, Israel, ²Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Neuropsychiatric lupus (NPSLE) is a common and prognostically significant manifestation of SLE, affecting 20-40% of lupus patients. The ACR identified 19 clinical syndromes associated…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 0709 • ACR Convergence 2025
Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Tracy Frech¹, Venkateswara Gogulamudi², Denisse Moreno², Eric Austin¹, Charles Frech³, Anna Hemnes¹, Tania Ruiz¹, Alex Shahin¹, Megha Talati¹, Colin Maguire⁴ and Anthony Donato², ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, ³Vanderbilt University, Nashville, TN, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: Systemic sclerosis (SSc) disease models that faithfully recapitulate endothelial mediated vasculopathy are critical for testing and developing novel treatments. The generation of inducible pluripotential…
Abstract Number: 0975 • ACR Convergence 2025
Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Xuezhi Hong¹, Yanhua Xiao², shihao zhu³, Tim Filla⁴, Andrea-Hermina Györfi⁵, Yi-Nan Li⁶, Meilin Xu⁷, Langxian Zhi², Thuong Trinh-Minh⁸, Clara Dees⁹, Georg Schett¹⁰, Jörg Distler¹¹ and Alexandru-Emil Matei¹², ¹Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, Düsseldorf, Germany, ²Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ³Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Düsseldorf, Germany, ⁸Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁹Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a progressive fibrotic disease characterized by fibroblast activation and immune dysregulation, with limited therapeutic options. Mitochondrial dysfunction is increasingly implicated…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0720 • ACR Convergence 2025
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Manuel Carpio Tumba¹, Aida Mohamadi², Diana Louden³, Victor Pimentel-Quiroz⁴, Michael Putman⁵, Didem Saygin⁶, Raisa Lomanto Silva⁷ and Sebastian E Sattui⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Washington, Seattle, WA, ⁴Universidad Científica del Sur, San Isidro, Peru, ⁵The Medical College of Wisconsin, Milwaukee, WI, ⁶Rush University Medical Center, Chicago, IL, ⁷Massachusetts General Hospital, Boston, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…
Abstract Number: 0904 • ACR Convergence 2025
SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
Jabea Ekabe¹, Ken Yasaka², Ruoqiao Wang³, Nida Pellett⁴, Javier Rangel-Moreno², Juilee Thakar³ and Jennifer Anolik⁴, ¹University of Rochester, Brighton, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, Rochester NY, ⁴University of Rochester Medical center, Rochester, NY
Background/Purpose: B cells contribute to rheumatoid arthritis (RA) pathogenesis through antibody-dependent and -independent mechanisms. Thus, identifying regulators of B cell fate in RA is essential…
Abstract Number: 0224 • ACR Convergence 2025
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 0985 • ACR Convergence 2025
Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
Hiroshi Kato¹, Lin Zhang¹, Mehrnaz Gharaee-Kermani², Amy Hurst¹, Rachael Bogle³, Alex Tsoi³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a frequent manifestation of systemic lupus erythematosus (SLE) and remains an important contributor to morbidity in lupus patients. Despite…
Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…
Abstract Number: 0603 • ACR Convergence 2025
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Amir Daneshvar¹, Areeb Tiwana², Dana Nachawati¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Canton Medical Education Foundation, Canton, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with widespread clinical manifestations. Neuropsychiatric SLE (NPSLE), a complex and poorly understood subset of SLE,…
Abstract Number: 0699 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is one of the life threatening complications of systemic sclerosis (SSc). Up to 20-50% require long term dialysis and subsequently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].